How do you know it is true? integrity in research and publications: AOA critical issue by Buckwalter, Joseph A. et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2015
How do you know it is true? integrity in research
and publications: AOA critical issue
Joseph A. Buckwalter
University of Iowa Hospitals and Clinics
Vernon T. Tolo
Keck School of Medicine at University of Southern California
Regis J. O'Keefe
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Buckwalter, Joseph A.; Tolo, Vernon T.; and O'Keefe, Regis J., ,"How do you know it is true? integrity in research and publications:
AOA critical issue." The journal of bone and joint surgery.97,1. e2. (2015).
http://digitalcommons.wustl.edu/open_access_pubs/3663
AOA Critical Issues
How Do You Know It Is True? Integrity in
Research and Publications
AOA Critical Issues
Joseph A. Buckwalter, MS, MD, Vernon T. Tolo, MD, and Regis J. O’Keefe, MD, PhD
High-quality medical care is the result of clinical decisions based upon scientiﬁc principles garnered from basic, translational,
and clinical research. Information regarding the natural history of diseases and their responses to various treatments is in-
troduced into the medical literature through the approximately one million PubMed journal articles published each year.
Pharmaceutical and device companies, universities, departments, and researchers all stand to gain from research publication.
Basic and translational research is highly competitive. Success in obtaining research funding and career advancement requires
scientiﬁc publication in the medical literature. Clinical research ﬁndings can lead to changes in the pattern of orthopaedic
practice and have implications for the utilization of pharmaceuticals and orthopaedic devices. Research ﬁndings can be biased
by ownership of patents and materials, funding sources, and consulting arrangements. The current high-stakes research en-
vironment has been characterized by an increase in plagiarism, falsiﬁcation or manipulation of data, selected presentation
of results, research bias, and inappropriate statistical analyses. It is the responsibility of the orthopaedic community to work
collaboratively with industry, universities, departments, and medical researchers and educators to ensure the integrity of the
content of the orthopaedic literature and to enable the incorporation of best practices in the care of orthopaedic patients.
The misrepresentation of natural observation has existed for
as long as scientiﬁc research has been recorded1,2. Ptolemy,
the renowned second-century Egyptian astronomer, recorded
astronomical measurements that he could not have made.
Ptolemy’s work, purporting to prove that Earth was the center
of the universe, inﬂuenced science and philosophy for centuries.
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an aspect of this work. In addition, one or more of the authors, or his or her institution, has had a ﬁnancial relationship, in the thirty-six months prior to
submission of thiswork, with an entity in the biomedical arena that could be perceived to inﬂuence or have the potential to inﬂuence what iswritten in this work.
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Copernicus, who revolutionized our understanding of both
Earth and man’s place in the universe, was accused of heresy
when he reported a conﬂicting celestial conﬁguration based
on appropriate scientiﬁc methods and accurate measurements.
The legendary physicist and Nobel laureate Robert Millikan
(1868-1953), who discovered the negative charge of the elec-
tron, selected only ﬁfty-eight of 140 observations for inclusion
in his scientiﬁc presentations. While this selective use of data
likely improved precision and the credibility of his claims, it did
not truly represent his actual scientiﬁc ﬁndings. Sir Cyril Burt
(1883-1971), a noted British psychologist, fabricated (extrap-
olated) data to show that human intelligence is 75% inherited.
His work inﬂuenced educational programs and policies for
generations.
Deﬁning Scientiﬁc Misconduct: From the Obvious to the
Subtle and Insidious
The U.S. Ofﬁce of Research Integrity deﬁnes misconduct as
“fabrication, falsiﬁcation, or plagiarism in proposing, perform-
ing, or reviewing research, or in reporting research results”
(http://ori.hhs.gov/deﬁnition-misconduct). Fabrication involves
the presentation of observations or events that in fact never
occurred; the experiments were never performed. Fabrication
continues to occur and in some cases has inﬂuenced the treat-
ment of patients withmusculoskeletal disease. From 1996 to 2008,
Dr. Scott Reuben published a series of articles that examined the
potential role of cyclooxygenase-2 (COX-2) speciﬁc inhibitors
in controlling postoperative pain following orthopaedic surgery.
In a series of carefully designed and double-blind placebo-
controlled studies, Dr. Reuben established that Celebrex (celecoxib;
Pﬁzer), Bextra (valdecoxib; Pﬁzer), and Vioxx (rofecoxib; Merck)
dramatically improved pain management for patients undergoing
joint replacement, spine fusion, and anterior cruciate ligament
reconstruction and decreased the complications associated with
the standard use of opiates3. Dr. Reuben, a Professor of Anes-
thesiology and Pain Medicine at Tufts and the Chief of Acute
Pain at Baystate Medical Center, was widely recognized for
revolutionizing pain management for orthopaedic patients.
A 2007 editorial in Anesthesia & Analgesia stated that Reuben
had been at the “forefront of redesigning pain management
protocols” through his “carefully planned” and “meticulously
documented studies4.”
In 2008, it was discovered that two abstracts submitted
by Dr. Reuben for Baystate Medical Center’s Annual Research
Week lacked institutional review board approval. Investiga-
tion showed that Dr. Reuben had never enrolled patients or
performed the studies described in the manuscripts. Further
review resulted in Baystate requesting medical journals to
retract a combined total of twenty-one of Dr. Reuben’s papers.
Dr. Reuben’s advocacy for COX-2 inhibitors to treat postop-
erative pain appeared in reviews, textbooks, and practice
guidelines. Beginning in 2000, Reuben advocated that physi-
cians should shift from the use of ﬁrst-generation nonsteroi-
dal anti-inﬂammatory drugs to the use of Vioxx, Celebrex,
and Bextra to treat musculoskeletal pain3. Reuben urged the
United States Food and Drug Administration (FDA) not to
restrict use of the drugs he studied, citing their efﬁcacy and
safety. Drug companies organized educational programs and
symposia on the basis of Reuben’s reports. Various editorials
noted that “millions of orthopaedic patients’ painmanagement
has been affected by Dr. Reuben’s research” and “Reuben’s
studies led to the sale of billions of dollars of Celebrex and
Vioxx.”5
In 2010, Reuben, who had research supported by Pﬁzer
and who served on a speaker’s panel for the company, was
sentenced to six months in prison, was ordered to pay a
$5000 ﬁne, and was required to provide $360,000 in restitution
to drug companies. To many, it was surprising that Reuben
could perform such extensive fabrication of high-impact re-
search for so long. Reuben had numerous coauthors and
worked in an academic institution where he successfully pro-
gressed through the promotion process5. These accounts dem-
onstrate the high level of trust afforded to scientists and reveal
that, although institutions approve research, they rarely mon-
itor the ﬁndings associated with that research5.
Falsiﬁcation involves the modiﬁcation of scientiﬁc data
so that it supports a particular hypothesis. In 1998, Dr. Andrew
Wakeﬁeld and coauthors published a study in The Lancet of
twelve children, suggesting a link between the measles, mumps,
and rubella (MMR) vaccine and autism6. The results were
widely reported by the media, were popularized on a variety
of web sites, resulted in the refusal of vaccination by many
parents, and led to lawsuits by parents of autistic children
against vaccine manufacturers. The Lancet and the press later
learned that Wakeﬁeld had received a $110,000 payment from
the Legal Aid Board prior to publishing the paper. The Legal
Aid Board was seeking evidence that could be used in lawsuits
against vaccine manufacturers and, following publication of
the article, provided an additional $674,000 payment to Wake-
ﬁeld. A retrospective review of the data used by Wakeﬁeld
revealed that the diagnosis and/or dates of records were changed
for all twelve children in the publication report so as to support
the author’s conclusions7,8.
The Lancet partially retracted Wakeﬁeld’s paper in 2004,
and later issued a full retraction. The General Medical Council
of the United Kingdom (U.K.) found Wakeﬁeld guilty of pro-
fessional misconduct and revoked his medical license. How-
ever, public suspicion that vaccinations can cause autism
persists. Vaccination rates have dropped sharply in many coun-
tries, including the United States, and this drop in vaccinations
is a major contributor to the increased incidence of measles and
mumps, resulting in outbreaks of the diseases and deaths in
multiple countries9. Subsequent studies have demonstrated no
link between theMMR vaccine and autism. Position statements
supporting vaccination and the absence of a link with autism
have been released by the Centers for Disease Control and
Prevention (CDC), the American Academy of Pediatrics, the
Institute of Medicine, the National Academy of Sciences, and
the U.K. National Health Service. Nonetheless, the general pub-
lic maintains a widespread belief in such an association. In
2012, the CDC reported a U.S. outbreak of whooping cough
that infected 41,000 children—the largest outbreak since 1955.
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This is an instance in which falsiﬁcation has compromised public
health worldwide.
Plagiarism is the inappropriate use of previously published
information without attribution and with representation that the
work is original. In 2011, an investigator reviewing the published
literature (the National Library of Medicine’s PubMed) related to
osteoarthritis discovered an article that had been published twice
in its entirety. The ﬁrst instance of publication was in 2006, when
the Journal of Orthopaedic Research published the paper with the
title, “Chondrocyte Gene Expression in Osteoarthritis: Correla-
tion with Disease Severity10.” In 2011, that same article was pub-
lished as “Alterations in Expression of Cartilage-Speciﬁc Genes
for Aggrecan and Collagen Type II in Osteoarthritis” in the Roma-
nian Journal of Morphology and Embryology11. The articles were
identical except for the titles and list of authors. Dr. Mogoanta,
Editor of the Romanian Journal of Morphology and Embryology,
withdrew the article, notiﬁed PubMed, banned the authors
from future publication, ceased collaboration with the reviewers,
notiﬁed the Dean of Medicine and Chair of the Ethics Commit-
tee, and coauthored an editorial for the Journal of Orthopaedic
Research12.
While the case of plagiarism is clearly against the rules,
stretching the boundaries of research ethics can be a more subtle
and insidious process. More subtle events include an intentional
failure to acknowledge previous work, intentionally incomplete
or inaccurate description of methods, and repeat publication of
similar work. In 2011, the Journal of Orthopaedic Research pub-
lished an editorial that was titled “Publishing the Results of
Multiple Experiments Using the Same Methods and Outcome
Measures.”13 The editorial described a scenario that occurred in
2002 and 2003 in which one author conducted a series of ex-
periments using the same methods, and a single control group,
to examine the effects of twenty-four different materials on bone
formation. The author subsequently reported positive results in
eleven publications, in ten different journals, over a period of
seven years. In some manuscripts, the author failed to cite the
previous publications, used the same description of themethods,
and published similar or nearly identical ﬁgures. The same con-
trol group was used in each study, but this fact was not reported
in the multiple publications.
Ensuring Accuracy in Research
The disclosure of conﬂicts of interest in publications and presen-
tations has become standard. However, standards at different
journals vary and typically do not involve detailed ﬁnancial infor-
mation. A study of disclosure at the 2012meeting of the American
Academy of Orthopaedic Surgeons revealed that 90% of the pre-
sentations had the required disclosure slide, but 10% did not14.
The average amount of time dedicated to the disclosure slide was
3.1 seconds, permitting only a cursory review of the information.
Only 45% of the disclosure slides had conﬂict-of-interest infor-
mation that included coauthors. Only 15% of the disclosure slides
had information regarding institutional conﬂicts14.
In a recent study in The Journal of Bone & Joint Surgery, a
signiﬁcant association was found between the funding source
and the qualitative conclusions in publications examining the
prevention of deep vein thrombosis following total joint arthro-
plasty15. From 2004 to 2010, sixty-six studies published in
PubMed-cited literature with identiﬁed industry or nonindustry
funding were reviewed to determine whether a treatment was
classiﬁed as favorable, neutral, or unfavorable in the prevention
of clotting. Only two of the ﬁfty-two industry-sponsored studies
had negative results, in contrast to negative ﬁndings being ob-
served in three of the fourteen studies without industry sup-
port15. A study of articles published in the MEDLINE database
between 1980 and 2002 revealed a signiﬁcant relationship be-
tween industry sponsorship and pro-industry conclusions16. The
odds ratio was 3.6. Khan et al. reported that in ﬁve major jour-
nals, between 2002 and 2004, there existed a strong statistical
link between industry funding and favorable outcomes17. While
these reports do not necessarily indicate wrongdoing, they sug-
gest possible increased risk of bias when interpreting results from
industry-sponsored clinical trials.
Many journals now include information about levels of
evidence based on trial design, and there has been a shift toward
more publications being conducted with a higher level of evi-
dence. The highest level of evidence is the placebo-controlled
double-blind clinical trial with appropriate power analysis and
statistical support. The lowest level of evidence involves the ed-
itorial or expert-opinion type of article (Fig. 1). The level of
evidence supporting presentations at the American Academy
of Orthopaedic Surgery meeting progressively increased from
2001 to 201018. The number of studies utilizing Level-I or
Level-II evidence has increased from 17% to 36% over that time
(Fig. 2)18. In an article published in 2008, Okike et al. stated that
their review of more than 1100 articles revealed that the major
scientiﬁc factor inﬂuencing acceptance for publication in The
Journal of Bone & Joint Surgery involved the level of evidence of
the article19.
Journals now use information technology to help ensure
the accurate and appropriate publication of research ﬁndings.
Many instances of dual publication and/or plagiarism are iden-
tiﬁed by plagiarism-checking software. Similarities in language
can be cross-referenced with all of the previously published
materials and scientiﬁc journals. When a certain threshold of
similarity is identiﬁed, a secondary review can be conducted.
Since 1975, there has been a tenfold increase in the num-
ber of journal articles that are retracted20. The likelihood of
retraction is greatest in high-impact journals that publish arti-
cles with substantial clinical relevance20. A high-proﬁle retrac-
tion of an article published in The Journal of Bone & Joint
Surgery (British volume—now known as The Bone & Joint
Journal) occurred in 200921,22. The manuscript showed that
the use of bone morphogenetic protein-2 (BMP-2) in open
tibial fractures in military service members improved healing
and reduced the need for subsequent surgery21,22. An inquiry
arose after the journal received a report that the coauthors had
not previously seen or approved the manuscript and that much
of the paper was essentially false. Further investigation by the
journal and byWalter Reed ArmyMedical Center (now known
as the Walter Reed National Military Medical Center) led to
retraction of the paper21,22. Fraud is the leading cause of journal
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retractions; approximately 68% of the cases of retraction due to
misconduct are the result of fraud, 43% are from duplicate
publication, and 14% are due to plagiarism20. Although the
number of retractions has markedly increased, these ﬁgures
still likely tremendously underestimate fraudulent behavior.
A conﬁdential analysis of research behaviors published inNature
Fig. 1
Levels of evidence in clinical trials. Thehighest level of evidence is the double-blind placebocontrolled research design (Level I). The lowest level of evidence
is the statement of expert opinion (Level V). (Table reproduced from Voleti PB, Donegan DJ, Baldwin KD, Lee GC. Level of evidence of presentations at
American Academy of Orthopaedic Surgeons annual meetings. J Bone Joint Surg Am. 2012;94:e50[1-5].)
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in 2005 showed extensive questionable ethical behavior23 (Fig. 3).
Surprisingly, senior scientists were more likely to engage in ques-
tionable behaviors23.
There were virtually no open-access journals in 1993. By
2009, more than 4500 open-access journals were in operation24.
The open-access journals are digital, online, free of charge, and
in most cases lack copyright restriction. While advertised as
“peer-reviewed” publications, the review process in many jour-
nals is cursory, and in some cases the review period is after
publication. Publication in open-access journals is costly for
authors. The Public Library of Science (PLOS) journals are
leaders in the open-access publishing environment and have
credibility. However, even the PLOS journals are very expen-
sive, with publication cost to the author ranging from $1300 to
$2900 per article, depending on the subspecialty journal. In
2011, the PLOS, BioMed Central, and Hindawi open-access
journals collectively published over 50,000 articles24. Thus, the
open-access publishing business has become a multimillion-dollar
business operation.
Despite safeguards, the likelihood that information en-
tering the publication process will later be disproved is quite
high. Dr. John Ioannidis has been a leader in evaluating the
tendency for published materials to be later proven incorrect,
incomplete, or inaccurate25. He has published these ﬁndings
both in scientiﬁc journals as well as in the popular press. His
work suggests that essentially all Level-IV evidence reports will
be proven false or inaccurate over time25. Up to 40% of articles
with Level-I evidence will also be disproved. He found that
randomized clinical trials, when repeated, show similar results
only two of every ﬁve times25.
A New Paradigm: The Burden of Proof
There has been general advocacy for stronger actions and in-
creased punishment for investigators participating in malfea-
sance in their research26. The implications of research ﬁndings
have ampliﬁed over time. The expenditure for drugs in 1990
was $40 billion. In 2008, the cost of prescription drugs in the
United States was $234 billion, accounting for approximately
10% of the cost of U.S. health care27. A recent publication has
noted that $3.6 billion was recovered in thirteen pharmaceuti-
cal fraud cases. Most of these cases were initiated by whistle-
blowers, and the pharmaceutical fraud cases collectively
accounted for approximately 40% of all federal fraud whistle-
blower recoveries27. As of July 2012, nine of the ten largest drug
companies were bound by corporate integrity agreements under
civil and criminal settlements or judgments in the United States28.
The British Medical Journal (now known as The BMJ) reported
that companies systematically planned complex marketing cam-
paigns to increase drug sales, including active promotion of off-
label drugs or otherwise inappropriate use of drugs, despite
knowledge that such use could seriously harm patients28.
Positive research ﬁndings in the high-stakes pharmaceutical
industry result in enormous ﬁnancial rewards and offer newmed-
ical treatments. Successful drug research and medical treatments
are innovative and at times push the boundary of public policy. An
example is the potential for stem-cell therapy to result in improve-
ments in tissue regeneration, to avert the process of aging, or to
treat inﬂammatory diseases. Several highly notable cases of stem-
cell fraud have gained public attention29,30. Fraudulent reports can
slow the progress of research, decrease the willingness of the pub-
lic to fund scientiﬁc discovery, and greatly enhance general skep-
ticism of the research community and its ﬁndings. Academic
medical centers also bear increased risk in this era of scrutiny.
After a recent case of fraud was discovered at Cornell Medical
Center and Weill College of Medicine, Cornell University
agreed to pay the government $4.4 million to settle a Justice
Department investigation31.
Technologies that are capable of examining large data sets
have increased the amount of scientiﬁc scrutiny that is being
performed. Search algorithms are available as a commercial
contracting enterprise, in some cases are publicly available,
and are sometimes proprietary research tools32. Both subspe-
cialty journals and high-impact scientiﬁc journals now publish
original articles that focus on large data sets that implicate
individual investigators in research fraud33-35. Similarly, individ-
ual web sites make accusations and speculate about research
fraud, and often publish this information on public web sites36.
While “whistleblower” activities can enhance integrity in
research, they are not foolproof. Investigators wrongly accused of
research fraud or malfeasance face an extraordinarily adversarial
environment. The burden of proof is not on the accuser but is on
the investigator to validate their research ﬁndings and integrity. In
many cases, the initial accusation is high proﬁle with widespread
coverage and interest. When the investigator is vindicated, the
announcements are lower proﬁle and frequently escape public
notice. A claim of fraud for any investigator typically results in a
formal review in an academic medical center, including the ap-
pointment of a committee to review the allegations. The investi-
gator is required to retain and make available all of the original
data and must report on the original data to the investigative
Fig. 2
Differences in level of evidence in support of clinical research studies
presented at the Annual Meeting of the American Academy of Orthopaedic
Surgeons, 2001 to 2010. LOE = level of evidence. (Table reproduced from
Voleti PB, Donegan DJ, Baldwin KD, Lee GC. Level of evidence of pre-
sentations at American Academy of Orthopaedic Surgeons annual meet-
ings. J Bone Joint Surg Am. 2012;94:e50[1-5].)
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committee. Ofﬁces of public relations and legal departments also
review these cases. A straightforward review process, given the
time required, the number of senior ofﬁcials involved in the
process, and the multiple reports generated, typically costs
between $20,000 and $50,000.
The research climate is high risk, particularly for inves-
tigators involved in industry-supported research involving
drugs with the potential for widespread clinical use. An exam-
ple is the approval of BMP-2 for use in spine fusions37. During
the FDA approval process, Medtronic supported seventeen
clinical trials. These studies resulted in multiple publications
and supported the use of BMP in spine fusion. However, ad-
ditional evidence, accumulated over time, identiﬁed potential
risk factors associated with BMP use in spine surgery. The
original publications received ongoing analysis and scrutiny in
the scientiﬁc literature and in the public press. Congressional
investigation ensued and the orthopaedic surgeons involved in
the studies were targeted in the press, in congressional hearings,
and in the scientiﬁc literature37. In response to these pressures,
Medtronic contracted with Yale University (Yale Open Data
Access project; YODA)38,39. Yale was given complete access to all
of the original data obtained in each of the Medtronic-sponsored
clinical trials. It is believed to be the ﬁrst time individual patient
data were made available in aggregate38,39. To eliminate conﬂict of
interest, Yale University served as a repository for the data but
subcontracted two other universities, the Oregon Health &
Sciences Center and the University of York in Great Britain,
to perform an analysis of the individual patient data40,41.
These reports were published in June of 201340,41. Both
groups independently performed an analysis that included an
aggregate of all individual patient data—an analysis that typi-
cally is not performed during the FDA approval process, but
that provides increased sensitivity for the identiﬁcation of rare
complications. The analysis of the aggregate individual patient
data was compared with a meta-analysis of the published
clinical trials, and to a meta-analysis of the conﬁdential clinical
trials reports from each of the seventeen Medtronic-sponsored
clinical trials that were submitted to the FDA. The aggregate
Fig. 3
Percentage of scientists admitting engaging in various questionable ethical behaviors at various career stages. (Reprinted by permission from Macmillan
Publishers Ltd: [Nature]; table reproduced fromMartinsonBC, AndersonMS, de Vries R. Scientists behaving badly. Nature. 2005 Jun9;435[7043]:737-8.)
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data suggested a higher incidence of complications40,41. The data
further showed that while BMP is effective, it does not result in
an incidence of spine fusion that is higher than what has been
associated with traditional treatment, with use of autologous
iliac crest bone graft40,41. The YODA initiative suggests that the
original conclusions and the published studies likely overesti-
mated the beneﬁt of BMP. Because this developed into a several
billion dollar per year industry, the research was high-stakes,
and skepticism developed regarding the integrity of the com-
pany and of the involved investigators, many of whom had
ﬁnancial relationships with Medtronic.
The Medtronic case has several important lessons. First,
investigators conducting high-proﬁle drug-related trials are at
risk for intense scrutiny; second, companies involved in such
studies may beneﬁt from providing open access to the data and/
or having the individual patient data from the individual trials
aggregated; and third, the YODA initiative may provide a new
model whereby the accuracy of clinical trials can be ensured,
and individuals and academic institutions can be shielded from
accusations of research fraud39.
Conclusions
Why do authors engage in misconduct? Science, being a high-
stakes enterprise, is based on the ability to produce new and
important observations. An academic and/or industry scien-
tiﬁc career is dependent on publication, which in turn has an
impact on continued employment, promotion, grant support,
personal recognition, and competition with other investiga-
tors. The current culture recognizes and celebrates discovery.
However, the tortuous path to discovery with use of rigorous
scientiﬁc principles, and the persistence required, are less
appreciated. Good scientists are conﬁdent, and the burden of
repeat experiments and the re-analysis of data can seem time-
consuming and unnecessary. Research progress is sped up
through deletion of “bad” data that can be rationalized and
justiﬁed inappropriately. The victims are the scientiﬁc and clin-
ical community and the patients whom they serve. Research
integrity remains a critical issue for the medical profession and
for orthopaedics, and it is not simply a problem for the research
community (Table I). The trends showing increasing instances
of malfeasance in research can be reversed only with the sus-
tained and collaborative effort of departments, medical centers
or institutions, professional societies, and journals. It is essen-
tial that we develop a strong culture of ethical awareness—one
that celebrates the integrity of the medical profession and the
knowledge that guides patient care.
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TABLE I Activities to Develop a Culture of Research Integrity
Department Establish research committees to approve studies and track progress
Yearly department clinical research retreats
Conferences, quality assurance, and grand rounds dedicated to research ethics
Special review and approval process for industry-supported research
Institution Educational programs in the ethics of research and publication
Statistics cores to ensure accurate interpretation and presentation of data
Masters and other degree-granting programs in clinical science designed for clinicians
Societies Develop Continuing Medical Education (CME) courses regarding ethics in research and clinical care
Symposia and conferences aimed at developing research expertise
Develop strict criteria for the reporting of conﬂict of interest
Journals Provide level of evidence for all published articles
Reviewer training in publication ethics and statistical analysis
Grading of statistics as a component of every article review
Author and coauthor conﬁrmation regarding the integrity of the data presented
Development of an ethics board to provide ﬁnal approval of manuscripts with conﬂict of interest
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